Identifying immunogenic CD4+ T-cell epitopes of Myeloid cell leukemia 1 using overlapping 20-mer peptides spanning the whole protein.

Research output: Chapter in Book/Report/Conference proceedingArticle in proceedingsResearchpeer-review

Myeloid cell leukemia 1 (Mcl-1) is an anti-apoptotic protein which is overexpressed in various
leukemia and other cancers [1]. Mcl-1 has a very short half-life [2], which has been suggested as a
molecular mechanism for cells to switch into either the survival or apoptotic pathways in response to
different stresses [3]. Recently, it has been demonstrated that downregulation of Mcl-1 by various
pharmacological agents or genetic approaches dramatically increases ABT-737 lethality in various
malignant cell types [4]. Different strategies for targeting Mcl-1 include (i) small interfering RNA [5]
(ii) small-molecule inhibitors [6] and (iii) peptide inhibitors [7]. In recent years, therapeutic
vaccination with synthetic peptides derived from anti-apoptotic proteins such as Mcl-1 has emerged
as a promising strategy against hematological cancers.
In this study, 34 overlapping 20-mer peptides, spanning the entire Mcl-1 protein, were adjuvanted
with cationic liposomes [8] and tested in three different mouse strains with varied Major
Histocompatibility Complex (MHC) haplotypes (FVB [H-2q], CB6F1[H-2b/d], B6CBAF1 [H-2b/k])
to identify immunogenic CD4+ T-cell epitopes.
Original languageEnglish
Title of host publication Proceedings of the 24th American Peptide Symposium Ved Srivastava, Andrei Yudin, and Michal Lebl (Editors) American Peptide Society
Number of pages2
Publication date2015
Pages262-63
Publication statusPublished - 2015

ID: 141470253